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Objectives. This report presents the 5-year results of the
Grampian Region Early Anistreplase Trial (GREAT) and quan-
tifies the benefit of earlier thrombolysis in terms that are gener-
ally applicable.
Background. Although it is accepted that the earlier thrombo-
lytic therapy is given for acute myocardial infarction the greater
the benefit, there are widely differing estimates of the magnitude
of the time-related benefit of thrombolysis because of inappropri-
ate trial design and analysis.
Methods. In a previously reported randomized trial, anis-
treplase (30 U) was given intravenously either before hospital
admission or in the hospital, at a median time of 105 and 240 min,
respectively, after onset of symptoms. Intention to treat and
multivariate analyses of the 5-year results were performed.
Results. By 5 years, 41 (25%) of 163 patients had died in the
prehospital treatment group compared with 53 (36%) of 148 in the
hospital treatment group (log-rank test, p < 0.025). Delaying
thrombolytic treatment by 1 h increases the hazard ratio of death
by 20%, equivalent to the loss of 43/1,000 lives within the next 5
years (95% confidence interval 7 to 88, p 5 0.012). Delaying
thrombolytic treatment by 30 min reduces the average expectation
of life by ;1 year.
Conclusions. The magnitude of the benefit from earlier throm-
bolysis is such that giving thrombolytic therapy to patients with
acute myocardial infarction should be accorded the same degree
of urgency as treatment of cardiac arrest. Policies should be
developed for giving thrombolytic therapy on-site if practicable
and by the first qualified person to see the patient.
(Am J Coll Cardiol 1997;30:1181–6)
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Although it is agreed that the earlier thrombolytic therapy is
given for acute myocardial infarction the greater the benefit
(1), there is no generally accepted figure for the magnitude of
the time-related benefit of thrombolysis. Some placebo-
controlled trials of thrombolytic therapy did not show any
greater benefit with earlier treatment (2,3), whereas at the
other extreme, it has been claimed that, in terms of its
potential for saving life, giving thrombolytic therapy is as
urgent as the treatment of cardiac arrest (4).
Much effort is required and is being expended to shorten
delays to thrombolysis, so it is important to quantify the benefit
of earlier thrombolysis to know whether the effort is likely to be
worthwhile.
In assessing the time-related benefit of thrombolytic ther-
apy, it is tempting to look only at the outcome of patients given
thrombolytic therapy at different times (e.g., while participat-
ing in clinical trials comparing different thrombolytic agents).
In such hospital-based trials of thrombolysis, treatment is
initiated as soon as practicable after the patient is admitted to
the hospital. The largest single component of the delay from
onset of symptoms until commencement of treatment is delay
by the patient in seeking medical assistance (5,6); but patient
delay is influenced by severity of infarction, and there is a
tendency for patients with poor left ventricular function and a
higher mortality risk to seek help earlier (7,8). This behavior
acts as a confounding factor, tending to mask the benefit of
earlier thrombolytic therapy; the sickest patients get the earli-
est treatment.
To quantify the time-related benefit of thrombolysis, time
of presentation has to be dissociated from time of initiating
treatment. Patients must be randomly allotted treatment on
presentation or after a deliberate delay. However, because it is
generally agreed that earlier thrombolytic therapy is more
beneficial, and only the magnitude of the time-related benefit
is unknown, it is considered unethical to impose a deliberate
delay in starting thrombolytic therapy. This ethical objection
may be overcome by randomly allocating patients to receive
thrombolysis before hospital admission or later, in the hospital.
The late treatment group then receives the best available
treatment, and the ethical objections are met. However, the
trial design is still not ideal because the later times of admin-
istration of thrombolysis before hospital admission may over-
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lap with the earlier times of administration in hospital (9). If
dose rather than time were being compared, an overlap of the
doses actually received in low and high dose groups would
vitiate the trial. The only way that a meaningful result could be
salvaged would be to abandon the intention to treat analysis
and construct a dose–response curve relating outcome to the
dose actually received.
The Grampian Region Early Anistreplase Trial (GREAT)
(10) was a randomized, double-blind, parallel-group trial of
anistreplase given either at the first opportunity before hospital
admission by general practitioners or later, in hospital in
Aberdeen. Grampian is a rural area of northeast Scotland, and
patients had to travel at least 30 min to reach the hospital. The
trial was conducted in this region to maximize the time
difference between prehospital and hospital administration.
The trial has been fully described, and the 1-year results were
reported by Rawles (11). In this report the 5-year results are
presented. Besides an intention to treat analysis, other analyses
are performed to construct the temporal equivalent of a
dose–response curve. An attempt is made to quantify the
benefit of earlier thrombolysis in terms that are generally
applicable away from the setting of the trial, for example, in
urban locations or in countries with different health care
systems.
Methods
Trial entry was for patients of any age, seen by their general
practitioners within 4 hours of symptom onset, with a strong
clinical suspicion of acute myocardial infarction and none of
the standard contraindications. The practices that participated
in the trial were located 16 to 62 miles (26 to 100 km) from the
hospital in Aberdeen to which all patients were referred
(average distance 36 miles [58 km]). The doctors were supplied
with paired ampoules of anistreplase (30 U) and matching
placebo, the ampoules being randomly labeled “home injec-
tion” or “hospital injection.” The home injection was given as
a slow intravenous injection by the general practitioner, and
the hospital injection was sent with the patient to the hospital,
where it was given by the hospital staff. Patients were person-
ally followed up for 1 year. Thereafter, we were notified of
deaths of trial patients by the Scottish Registry Office.
Follow-up is complete to 5 years; all data beyond 5 years are
censored.
Statistical analyses. Statistical analyses were performed
using SPSS release 6.1.3. Survival in the two groups is depicted
using Kaplan-Meier curves and compared using the log-rank
test.
Using the Cox proportional hazards model, survival in the
two groups combined was regressed stepwise against random-
ization assignment; age; gender; previous myocardial infarc-
tion; and patient delay in seeking help, time of randomization,
time of administration of anistreplase and the logarithms of
these three time delays. The logarithms were included because
of the possibility that the effect of any of these delays might be
nonlinear, with a greater effect sooner rather than later after
start of symptoms. The stepwise analysis selects variables
according to their significance, which was set at p , 0.05.
Multiple logistic regression analysis was also used to regress
death within 5 years against the same predictor variables.
Results
Intention to treat analysis. Three hundred eleven patients
were recruited: 163 to the “prehospital” group, 148 to the
“hospital” group. The two groups were similar in baseline
comparisons; mean age was 63.4 years (range 32 to 93) (10).
Time of thrombolysis (Fig. 1). The median time after symp-
tom onset to administration of anistreplase was 105 min (range
25 to 390) in the prehospital group and 240 min (range 80 to
540) in the hospital group. The cumulative percent of patients
in each group who had received treatment by various times is
shown in Figure 1. Although the medians are separated by
135 min, the times of administration of thrombolytic therapy in
one group overlap those of the other group in 254 (82%) of 311
cases.
Mortality. By 5 years, 41 (25%) of 163 patients had died in
the prehospital group compared with 53 (36%) of 148 in the
hospital group. Kaplan-Meier survival curves for prehospital
and hospital groups are shown in Figure 2, and these are
separate throughout the 5-year follow-up period. Mean sur-
vival in the prehospital group was 1,517 days compared with
1,309 days in the hospital group (difference 208 days, 95%
confidence interval [CI] 42 to 374, p , 0.025 [log-rank test]).
Multivariate analysis. The extent of overlap in the times of
administration of thrombolytic therapy in prehospital and
hospital groups, illustrated in Figure 1, diminishes the ability of
the trial to demonstrate a difference in outcome between
randomized groups. An alternative approach is to combine the
Abbreviations and Acronyms
CI 5 confidence interval
EMIP 5 European Myocardial Infarction Project
FTT 5 Fibrinolytic Therapy Trialists’ Collaborative Group
GREAT 5 Grampian Region Early Anistreplase Trial
MITI 5 Myocardial Infarction Triage and Intervention trial
TIMI 5 Thrombolysis in Myocardial Infarction
Figure 1. Cumulative percent of patients in the prehospital, hospital
and combined groups who had received thrombolytic treatment at
various times.
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two groups and perform multivariate analysis to quantify the
relation between time of thrombolysis, illustrated by the mid-
dle line in Figure 1, and outcome. The median and mean times
of administration of anistreplase for the combined group of
patients were 180 and 188 min, respectively.
Age (coefficient 0.0812, p , 0.0001) and time of anis-
treplase administration (coefficient 0.0030, p 5 0.0025) were
the two predictor variables selected for inclusion in the Cox
proportional hazards model. The same two predictor variables
were selected by multiple logistic regression analysis (coeffi-
cients: constant 28.0405, p , 0.0001; age 0.0995, p , 0.0001;
thrombolysis time 0.0036, p 5 0.0119). The selection of time
of anistreplase administration rather than randomization
assignment indicates that the essential difference between
the prehospital and hospital groups is the timing of throm-
bolysis.
Age. The hazard ratio for age 60 years, less than the
average of 63.4 years, is 0.755, whereas that for age 70 years is
1.701, an increase of 225% over the decade. The relation
between age at trial entry and probability of dying within the
next 5 years is illustrated in Figure 3.
Time of anistreplase administration. The hazard ratio for
anistreplase given 30 min earlier than average is 0.914, whereas
if given 30 min later than average, it is 1.094, an increase of
20% over the hour. By logistic regression, a 1-h delay in giving
anistreplase is equivalent to 43/1,000 additional deaths within 5
years (95% CI 7/1,000 to 88/1,000, p 5 0.012). This is the
average gradient of the regression line in Figure 4 relating time
of thrombolysis to the probability of death within 5 years.
Comparison of Figures 3 and 4 shows that a delay in giving
thrombolytic therapy of 5 h increases the probability of dying
within 5 years by about the same amount as an increase in age
from 60 to 70 years. Delay in giving thrombolytic treatment by
30 min is equivalent to aging by 1.11 years, or loss of life
expectation of ;1 year (30 min 3 0.0030 5 1.108 years 3
0.0812).
Discussion
In GREAT (10), two groups of patients with suspected
acute myocardial infarction that were similar in all other
respects were randomly allotted thrombolytic therapy before
hospital admission, within 2 h of symptom onset, or in hospital,
.2 h later. At 1 month, although there was a mortality
difference of 6% in favor of prehospital thrombolysis, this did
not reach conventional statistical significance (p 5 0.07), but
by 1 year it was 11% and was highly significant (p 5 0.007)
(11). The present analysis reports that the mortality difference
has been maintained throughout the follow-up period, and is
11% at 5 years (p 5 0.025).
GREAT, completed .5 years ago, was carried out in a rural
location in the northeast of Scotland, where general practitio-
ners still make home visits. Does it have any relevance for
cardiologists practising in the United States? Are the results in
any way applicable to urban areas or to hospitals with a
fast-track system for dealing with patients with acute myocar-
dial infarction?
In the present report the 5-year results of GREAT were
used as the basis for multivariate analysis of the pooled data
from both groups, enabling the general relation between time
of thrombolysis and outcome to be quantified regardless of
whether thrombolysis is given at home or in-hospital. The
benefits of earlier thrombolysis derived from this analysis are
calculated as hazard ratios, but more accessibly, as lives saved
per hour of earlier treatment. Also calculated is the effect of
thrombolysis delay on expectation of life. Expressed in these
ways, the results should be widely relevant to current practice
in any health care system.
Delay in giving anistreplase by 1 h increases the hazard
ratio for death by 20%, equivalent to 43/1,000 additional
deaths within the next 5 years. Delaying thrombolytic therapy
by 5 h is equivalent to aging by 10 years. A delay of 30 min
results in a reduction of life expectation of ;1 year. How do
these estimates of time-related benefit compare with others?
Figure 2. Kaplan-Meier survival curves for patients in the prehospital
and hospital groups.
Figure 3. Relation between age at trial entry and probability of dying
within 5 years.
Figure 4. Relation between timing of anistreplase administration and
probability of dying within 5 years. Dashed lines 5 95% confidence
intervals.
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The Fibrinolytic Therapy Trialists Collaborative Group
(FTT) estimate of the benefit/time gradient. The most author-
itative estimate of the time-related benefit of thrombolytic
therapy comes from the FTT (12) overview of all nine random-
ized trials of .1,000 patients in which thrombolytic therapy is
compared with placebo. The data are classified into five time
periods from 0 to 24 h from onset. In each time period, the
mortality rate in patients given thrombolytic therapy is less
than that in those given placebo, and the absolute benefit is
greater with earlier treatment. Regression of benefit by time of
randomization yields a straight line with an intercept of
35/1,000 at time zero, and zero benefit at 21.5 h after onset; the
gradient indicates a loss of benefit of 1.6/1,000 per h of delay.
The benefit/time gradient derived from the FTT overview is
so low that many would consider that any great effort in
expediting thrombolysis would not be justified, particularly the
effort required to take thrombolytic therapy out of the hospital
and into the community. However, the FTT estimate may be
criticized on three grounds.
Thrombolytic therapy is beneficial by causing the throm-
bosed infarct-related artery to be reperfused—the “open ar-
tery hypothesis” (13); but the mechanism of benefit depends
on how quickly reperfusion occurs. If within 2 h of onset,
reperfusion results in myocardial salvage, which is steeply time
dependent (14–16). By 6 h, myocardial salvage is all over (17),
but an open artery confers electrical stability on the infarct
(18,19) and reduces infarct expansion and remodeling (20–22).
These late mechanisms are only weakly time dependent, if at
all. It is therefore inherently unlikely that the mortality/time
benefit of thrombolytic therapy would be best represented by a
straight line. A nonlinear statistical model with a steeper
gradient with earlier treatment is to be expected; a straight line
that predicts a benefit of only 35/1,000 when thrombolytic
therapy is given at time zero is almost certainly wrong.
In the FTT overview, the mean time of randomization was
6.7 h after onset; only 7% of patients were randomized, and
even fewer received thrombolytic treatment, within 2 h. Pre-
diction of benefit within 2 h, when myocardial salvage is the
predominant mechanism of benefit, is therefore heavily
weighted by what happens to the bulk of patients who are given
thrombolytic therapy after 2 h and who benefit from a different
mechanism. Moreover, the time periods are too wide to show
important detail within them. For example, it is likely that the
benefit in the first hour is higher than in the second hour, yet
these two time periods are combined.
However, the most cogent criticism of the FTT estimate of
the benefit/time gradient is that it is methodologically incor-
rect. It is a fundamental principle of clinical trial design that
comparisons are made between groups that are determined by
a random process; but the temporal groups in the FTT analysis
were determined by the time of presentation of patients in
hospital. It is as if, in a dose comparison trial, the patients
themselves were to decide which dose to take; there is the
possibility of bias from sicker patients choosing a higher dose.
In a nonrandomized time-comparison study, there is the
possibility that sicker patients may get earlier treatment; the
time-related benefit would then be underestimated. Within the
FTT data there is evidence that this is so. The mortality rate in
patients given thrombolytic therapy at 2 to 4 h is 8.4%, but the
mortality rate in those who are treated at 0 to 2 h is not lower,
as expected, but slightly higher at 9.3%. The reason for this
finding is seen in the mortality rates in the placebo group:
There also the rate is higher at the earlier than at the later time
(13.2% vs. 11.4%); patients with a higher mortality risk are
treated earlier. Because of this bias, the benefit/time gradient
cannot be calculated from these data, either by comparison of
mortality rates in patients given thrombolytic therapy at dif-
ferent times or by reference to a control group: There is not
one control group but several that are demonstrably different
from each other. To determine the benefit/time gradient we
have to know what the mortality rate would have been for
patients presenting at one time and being treated at another.
However, this experiment was not done, and time of presen-
tation and time of treatment were always closely associated.
The criticisms of the FTT estimate of time-related benefit
of thrombolytic therapy may be summarized as follows: a linear
statistical model, underrepresentation of early-treated patients
and nonrandom determination of time of treatment. Despite
these criticisms having been voiced, members of the FTT have
recently dismissed these objections and claimed that their
estimate of the benefit/time gradient is correct (23).
Other estimates of the time-related benefit of thrombolysis.
In the Thrombolysis in Myocardial Infarction (TIMI)-II trial
(24) it was observed that for each hour of earlier treatment, the
absolute mortality rate fell by 10/1,000. In that analysis (24)
four treatment periods of 1 h were considered from 0 to 4 h
after onset of symptoms. However, apart from the narrower
time periods, the same criticisms apply here as are leveled at
the FTT analysis: a linear model, underrepresentation of early
patients and nonrandom determination of time of treatment.
Criticism of the FTT benefit/time gradient comes also from
the Rotterdam group (25), who extended the FTT database to
include all 22 randomized trials that compare thrombolytic
therapy and placebo and have $100 patients. The results in all
the temporal subgroups reported in these trials were kept
separate for a benefit/time analysis. A nonlinear relation
between benefit and time of randomization was demonstrated
and was significantly better than a linear model; Figure 5
illustrates the benefit/time regression obtained. Initially the
gradient is steep, but there is an inflection at ;2 h, after which
Figure 5. Relation between absolute mortality benefit and time of
randomization to thrombolytic therapy. Data from Boersma et al. (25).
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the benefit is much less time dependent. This shape of curve is
what might be expected theoretically and reflects the different
mechanisms of benefit at different times. The model uses a
reciprocal term, so the predicted absolute benefit at time zero
is infinite, but at 30 min it is 78/1,000. The benefit predicted at
1.5 h from onset is 38/1,000, and at 2.5 h 30/1,000. The mean
benefit/time gradient at 2 h is therefore 8/1,000 per h, whereas
at 4 h it is 3/1,000 per h. Although not guilty of forcing the data
into a linear model, that analysis, like that of the FTT, is flawed
by a nonrandom determination of time of treatment. If sicker
patients receive earlier treatment, then the benefit of earlier
treatment will be underestimated.
Randomized trials of prehospital thrombolysis. The only
way in which the time-related benefit of thrombolysis may be
properly quantified is with a trial in which the time of
administration of therapy is randomly determined. To meet
ethical objections to introducing any avoidable delay, the early
group is given treatment before hospital admission and the late
group in the hospital. Eight such trials have been reported,
with a combined total of 6,607 patients; GREAT (10) is the
third largest of these trials, being exceeded in size by the
European Myocardial Infarction Project (EMIP) (26) (n 5
5,469) and the Myocardial Infarction Triage and Intervention
trial (MITI) (27) (n 5 360); there are five other trials with 57
to 145 patients. All but one of these trials have shown a
tendency toward a lower mortality with prehospital thrombol-
ysis, but in none has this been significant at 1 month. However,
a meta-analysis (25) gives an average benefit/time gradient of
21/1,000 per h (SE 6), with a highly significant (p 5 0.002)
mortality reduction in favor of prehospital thrombolysis (25).
This, then, is the best available estimate of the time-related
benefit of thrombolysis, being based on intention to treat
analyses of appropriately designed trials using a variety of
thrombolytic agents.
This estimate of the benefit/time gradient, 21/1,000 per h, is
.10 times as great as that of the FTT and twice as great as that
from TIMI-II. It is entirely consistent with that from GREAT,
which, of course, contributed to it. The mortality difference at
1 month in GREAT was 6% for a 135-min difference between
median times of administration of prehospital and hospital
thrombolytic therapy. The crude benefit/time gradient is there-
fore 27/1,000 per h and by multivariate analysis 21/1,000 per h
(4).
The benefit/time gradient of 43/1,000 per year calculated in
the present report is based on 5-year results from GREAT.
Between 1 month and 1 year, the difference in mortality
between prehospital and hospital groups increased from 6% to
11%, and that difference is still present at 5 years. Late
mortality benefit from thrombolytic therapy is not unexpected
if thrombolysis is early enough to result in myocardial salvage.
Death from heart failure or recurrent infarction is less likely if
myocardial loss in the index event is minimized. The estimates
of the time-related benefits of thrombolysis derived from
GREAT and reported in the present analysis are plausible and
entirely consistent with those from the meta-analysis of ran-
domized trials of prehospital thrombolysis.
Implications of the benefit/time gradient. On the basis of
an estimated benefit/time gradient of 10/1,000 per h derived
from TIMI-II, Cannon et al. (24) concluded that “the treat-
ment of patients with an acute MI [myocardial infarction]
should take on the urgency of a cardiac arrest.” The present
study, based on a trial of appropriate design, and taking
deferred mortality benefit into account, suggests that the
benefit/time gradient may be four times as steep as that
estimated from TIMI-II.
The saving of life by resuscitation in out of hospital cardiac
arrest in patients with an acute myocardial infarction has been
estimated at 10 to 30/1,000 (28). If the response of the
emergency services to calls from patients with an acute myo-
cardial infarction is delayed by 1 h, 10 to 30/1,000 additional
patients will die before admission to hospital. However, if
thrombolytic therapy is delayed by 1 h, 21/1,000 additional
patients will die in the first month and at least as many again in
the next few years. Thus, in terms of potential for saving life,
giving thrombolytic therapy may justifiably be considered as
urgent as the treatment of cardiac arrest. If this claim seems
exaggerated, we should recall that, given early enough, reper-
fusion therapy is a radical treatment for acute myocardial
infarction, whereas all other treatments, including defibrilla-
tion, are palliative.
If these arguments are accepted, then it follows that, as in
cardiac arrest, treatment should be initiated at the first oppor-
tunity, on-site if practicable, and by the first qualified person to
see the patient. Doctor to doctor referrals for thrombolytic
therapy should be unacceptable, as they would be for initiating
treatment for cardiac arrest. We require doctors to be compe-
tent at resuscitating patients in cardiac arrest; thus, it would
not be unreasonable to expect all frontline doctors to be
competent also at diagnosis and treatment of coronary throm-
bosis.
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